Thrombolytic Science has announced that the Turkish Ministry of Health, through the Turkish Medicines and Medical Devices Agency (TİTCK), has authorised the initiation of PROMPT-STEMI, a phase 2 clinical trial evaluating its mutant prourokinase (mproUK)-based sequential fibrinolytic approach in patients with ST-segment elevation myocardial infarction (STEMI). The study is sponsored by TSI Türkiye, and the […] The post PROMPT-STEMI trial gets green light to begin appeared first on Cardiovascular News .